OS Therapies Files 8-K on Financials

TL;DR

OS Therapies filed an 8-K on Nov 15th detailing financial condition. No major news yet.

AI Summary

On November 15, 2024, OS Therapies Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.

Why It Matters

This filing provides an update on OS Therapies Inc.'s operational and financial status, which is crucial for investors to assess the company's performance and outlook.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting financial condition and results of operations, with no immediate indication of significant positive or negative developments.

Key Players & Entities

• OS Therapies Inc. (company) — Registrant
• November 15, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 20850 (zip_code) — Business address zip code
• 410-297-7793 (phone_number) — Business phone number

FAQ

Key Financial Figures

• $0.001 — ch Registered Common Stock, par value $0.001 per share OSTX NYSE American Indi

Filing Documents

• ea0221417-8k_osthera.htm (8-K) — 27KB
• ea022141701ex99-1_osthera.htm (EX-99.1) — 14KB
• 0001213900-24-099094.txt ( ) — 217KB
• ostx-20241115.xsd (EX-101.SCH) — 3KB
• ostx-20241115_lab.xml (EX-101.LAB) — 33KB
• ostx-20241115_pre.xml (EX-101.PRE) — 22KB
• ea0221417-8k_osthera_htm.xml (XML) — 4KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 OS THERAPIES INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-42195 82-5118368 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 115 Pullman Crossing Road , Suite 103 Grasonville , Maryland 21638 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: ( 410 ) 297-7793 N/A (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share OSTX NYSE American Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. CURRENT REPORT ON FORM 8-K OS Therapies Incorporated November 15, 2024 Item 2.02. Results of Operations and Financial Condition. On November 15, 2024, OS Therapies Incorporated, an ADC and immunotherapy research and clinical-stage biopharmaceutical company, issued a press release announcing its financial results for the third quarter ended September 30, 2024. A copy of the press release is furnished with this report as Exhibit 99.1. Such information, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release issued by OS Therapies Incorporated on November 15, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OS THERAPIES INCORPORATED Dated: November 15, 2024 By: /s/ Paul A. Romness, MPH Name: Paul A. Romness, MPH Title: President and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR